PML/RARα transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation

Leukemia

Volumn 10, Issue 2, 1996, Pages 207-212

  Perego, R A ^a,c   Marenco, P ^b   Bianchi, C ^a   Cairoli, R ^b   Urbano, M ^a   Nosari, A M ^b   Muti, C ^b   Morra, E ^b   Del Monte, U ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c Institute of General Pathology   (Italy)

Author keywords

Acute; Bone marrow transplantation; Minimal residual disease; PML RAR transcript; Promyelocytic leukemia; Reverse transcriptase polymerase chain reaction

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0029670541     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Warrell RP Jr, de Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. New Engl J Med 1993; 329: 177-189.
2. Grignani F et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10-25.
3. Pandolfi PP et al. Genomic variability and alternative splicing generate multiple PML/RARα transcripts that encode aberrant PML protein and PML/RARα isoforms in acute promyelocytic leukaemia. EMBO J 1992; 11: 1397-1407.
4. Biondi A et al Molecular monitoring of the myl/retinoic acid receptor-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80: 492-497.
5. Chen SJ et al. Occurrence of distinct PML-RAR-α fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction. Oncogene 1992; 7: 1223-1232.
6. Miller WH Jr et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 1993; 82: 1639-1694.
7. Huang W et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 1993; 82: 1264-1269.
8. Vahdat L et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843-3849.
9. Grignani F et al. The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74: 423-431.
10. Huang M et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
11. Gambacorti-Passerini C et al. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein PML/RARα present in acute promyelocytic leukemia cells. Blood 1993; 81: 1369-1375.
12. Lo Coco F et al. PML/RAR-α rearrangement in acute promyelocytic leukaemias apparently lacking the t(15;17) translocation. Eur J Haematol 1992; 48: 173-176.
13. Miller WH Jr et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89: 2694-2698.
14. Lo Coco F et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992; 340: 1437-1438.
15. Laczika K et al. Rapid achievement of PML-RARα polymerase chain reaction (PCR)-negativity by combined treatment with all-trans retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study. Leukemia 1994; 8: 1-5.
16. Fenaux P et al. Treatment of acute promyelocytic leukemia: a report of 70 cases. Leuk Lymphoma 1991; 4: 239-248.
17. Cortes JE et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994; 73: 2946-2952.
18. Avvisati G et al. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 1990; 44: 257-260.
19. Avvisati G et al. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL): experience of the Italian cooperative group GIMEMA. Blood 1993; 82 (Suppl. 1): 250a.
20. Zittoun RA et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med 1995; 332. 217-223.
21. Avvisati G et al. AIDA protocol (all-trans retinoic acid + idarubicin) in the treatment of newly diagnosed acute promyelocytic leukemia (APL): a pilot study of the Italian cooperative group GIMEMA. Blood 1994; 84 (Suppl. 1): 380a.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidmium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
23. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237-238.
24. Giguere V, Ong ES, Segui P, Evans RM. Identification of a receptor for the morphogen retinoic acid. Nature 1987; 330: 624-629.
25. Bianchi C et al. Detection by polymerase chain reaction of BCR/ABL transcripts in myeloproliferative diseases at time of diagnosis and for monitoring chronic myelogenous leukaemia patients after bone marrow transplantation. Eur J Cancer 1995; 31A: 197-201.
26. Seale J et al. Quantitative assessment of minimal residual disease in acute promyelocytic leukemia by RT-PCR: evaluation of techniques to improve sensitivity. Blood 1994; 84 (Suppl. 1): 301a.
27. Saunders MJ, Tobal K, Liu Yin JA. Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation. Leuk Res 1994; 18: 891-895.
28. Fenaux P. Management of acute promyelocytic leukemia. Eur J Haematol 1993; 50: 65-73.
29. Eardley AM, Heller C, Warrell RP Jr. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia. Leukemia 1994; 8: 934-939.
30. Degos L et al. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643-2653.
31. Frassoni F et al. Are patients with acute leukemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Leukemia 1994; 8: 924-928.
32. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 1994; 84: 3603-3612.
33. Mandelli F et al. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Bone Marrow Transplant 1994; 14: 293-298.
34. Cao LX et al. Bone marrow transplantation for the treatment of AML-M3 patients with complete remission by all-trans retinoic acid. Exp Hematol 1994; 22: 692.
35. Hewlett J et al. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study. Leukemia 1995; 9: 562-569.
36. Fukutani H et al. Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. Leukemia 1995; 9: 588-593.